Skip to main content

Advertisement

Table 2 Significant regions

From: Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas

cytoBand (+ gain, - loss) Mbp startPos (BAC) Mbp endPos (BAC) Size (Mbp) cases resistant (%) cases sensitive (%) P-value No. of genes
+ 3q26.2 170150001 (RP11-152C17) 170300002 (RP11-252J1) 0.15 65 20 0.0095 2
- 6q11.2-12 63400001 (RP11-692G18) 68250002 (RP11-164N24) 4.85 40 0 0.0033 16
- 9p22.3 15100001 (RP11-271D19) 16150002 (RP11-141K7) 1.05 45 5 0.0084 6
- 9p22.2-22.1 17750001 (RP11-601F21) 18550002 (RP11-269F13) 0.8 45 5 0.0084 2
- 9p22.1-21.3 19650001 (RP11-61D22) 20800002 (RP11-66P3) 1.15 45 5 0.0084 3
- Xp22.2-22.12 15250001 (RP11-438H12) 20750002 (RP11-451E9) 5.5 60-65 15 0.0031-0.0079 39
- Xp22.11-11.3 24050001 (RP11-79B3) 46900002 (RP11-571E6) 22.85 60-70 15-20 0.00077-0.0095 141
- Xp11.23-11.1 49250001 (RP11-122N23) 58250002 (RP11-96A5) 9 60-65 10-15 0.00077-0.0079 85
  1. Regions exhibiting statistical significance (P < 0.01) between sensitive and resistant cases. The intervals in frequency numbers and P-values are due to CNA gaps inside the significant regions.